Mass tort lawsuit · Checked on November 3, 2026
Ozempic lawsuit (GLP-1 stomach injury): status November 2026
Yes, the Ozempic lawsuit is active. About 4,082 lawsuits were pending in federal MDL 3094 on November 2, 2026, according to the court panel's report. Plaintiffs allege that GLP-1 drugs such as Ozempic, Wegovy and Mounjaro caused gastroparesis (stomach paralysis), ileus or bowel blockage. No trial date or settlement has been announced.
| Case | MDL 3094 |
|---|---|
| Court | U.S. District Court, Eastern District of Pennsylvania |
| Judge | Karen S. Marston |
| Pending cases | 4,082 (as of November 2, 2026) |
| Stage | Discovery and expert rulings; no trial date or settlement announced |
| New cases | Law firms are filing new cases |
| Next scheduled date | None announced in the records we checked |
| Last checked | November 3, 2026 |
What plaintiffs allege
Plaintiffs allege that Novo Nordisk and Eli Lilly did not adequately warn that their GLP-1 receptor agonist drugs (semaglutide: Ozempic, Wegovy, Rybelsus; tirzepatide: Mounjaro, Zepbound; and others such as Trulicity, Victoza and Saxenda) could cause gastroparesis, ileus and intestinal obstruction. The companies deny the claims.
Where the case stands
- The cases are combined before Judge Karen S. Marston in Philadelphia (verified, JPML report).
- In August 2025 the court addressed how a gastroparesis diagnosis must be shown, including the role of a gastric emptying study (reported).
- No bellwether trial date and no settlement had been announced as of our check (reported).
- A separate MDL covers vision loss claims (NAION): see Ozempic vision loss lawsuit.
Settlement status
No settlement had been announced as of November 3, 2026. We report a settlement only when a court order, a company filing or a company statement confirms it, and we never estimate payment amounts.
Updates
Newest first. Each entry says whether we read the record ourselves (verified) or it comes from coverage (reported).
- November 2026: The federal panel's report of November 2, 2026 listed 4,082 pending cases (verified, JPML report).
- October 2026: The federal panel's report of October 1, 2026 listed 4,025 pending cases (verified, JPML report).
- August 2025: The court addressed how a gastroparesis diagnosis must be shown, including the role of a gastric emptying study (reported).
What law firms commonly ask callers
Law firms reviewing these cases usually ask about the following. This is general information, not an assessment of any claim:
- which GLP-1 drug was used and when
- whether a doctor diagnosed gastroparesis, ileus or a bowel obstruction after starting it
- whether a gastric emptying study was done
- hospital or emergency records
Questions
Is the Ozempic lawsuit real?
Yes. The U.S. Judicial Panel on Multidistrict Litigation listed 4,082 pending cases in MDL 3094 as of November 2, 2026 (verified). A pending case is a claim filed in court, not a finding that the claim is true.
When will the Ozempic lawsuit settle?
Nobody can predict when or whether a mass tort will settle. What has been disclosed so far: No settlement had been announced as of November 3, 2026. We report a settlement only when a court order, a company filing or a company statement confirms it, and we never estimate payment amounts.
Can Ozempic cause gastroparesis?
That is what the lawsuits allege, and the companies deny it. No court has made a final decision on that question. For medical questions, talk to your doctor.
Is there an Ozempic class action?
The Ozempic cases are a mass tort, not a class action: each person files their own lawsuit, and the federal cases are combined in MDL 3094 for pretrial work.
Has there been an Ozempic settlement?
No settlement had been announced as of November 3, 2026.
Sources
- JPML, Pending MDL Dockets by Actions Pending, November 2, 2026 verified
- U.S. District Court E.D. Pa., MDL 3094 page verified
- Drug and Device Law blog on the August 2025 ruling reported
Verified means we read the court, agency or company record ourselves on the check date. Reported means the fact comes from news or law firm coverage and could not be confirmed on a primary record.